Shilpa Medicare has received establishment inspection report (EIR), from United States Food and Drug Administration (USFDA).
The company has received of EIR for both API manufacturing facilities located at Raichur, Karnataka, from USFDA. This inspection was carried out between 16 to 19 January, 2018 and the inspection has now been closed by USFDA.
